Long-Term Safety and Efficacy Data of Golodirsen in Ambulatory Patients with Duchenne Muscular Dystrophy Amenable to Exon 53 Skipping: A First-in-human, Multicenter, Two-Part, Open-Label, Phase 1/2 Trial.

Autor: Servais, Laurent, Mercuri, Eugenio, Straub, Volker, Guglieri, Michela, Seferian, Andreea M., Scoto, Mariacristina, Leone, Daniela, Koenig, Erica, Khan, Navid, Dugar, Ashish, Wang, Xiaodong, Han, Baoguang, Wang, Dan, Muntoni, Francesco, Brusa, Chiara, Antonaci, Laura, Brogna, Claudia, Merli, Laura, Monforte, Mauro, Norcia, Giulia
Zdroj: Nucleic Acid Therapeutics; Feb2022, Vol. 32 Issue 1, p29-39, 11p
Databáze: Complementary Index